Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPriority Health Medicare Part B Prior Auth Update …
    Ask Trek AI about this page
    Currentpriority healthPolicy N/A

    Medicare Part B Prior Authorization and Step Therapy Criteria

    Customize your policy alerts

    Sign up for all priority health policy alerts

    Know when priority health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization and step therapy requirements for Medicare Part B (medical) drugs administered by providers, including criteria, exclusions, documentation, and product-specific rules for Priority Health Medicare Advantage enrollees.

    Policy Summary
    Payerpriority health
    PolicyMedicare Part B Prior Authorization and Step Therapy Criteria
    Policy CodePolicy N/A
    Change TypeAdministrative review — no material changes
    Effective DateMay 1, 2026
    Last ReviewMay 1, 2026
    Next Review DateN/A
    Key ActionSubmit the Medicare Part B drug request form or Web Form with required medical records to request prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3products detailed in this segment
    Hydroxyurea 6mostep therapy example (Adakveo)
    >=150eosinophil threshold (Cinqair)
    12Evenity lifetime limit (months)

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    1-2 yr
    typical approval duration

    Policy Overview & Scope

    Part B drug (definition)
    DefinitionOutpatient prescription drugs and biologicals administered by infusion or injection furnished incident to a physician or provider service and not usually self‑administered by the patient.
    Typical settingAdministered in infusion center, office, or hospital outpatient setting.
    Coverage contextEligible for Medicare Part B when furnished incident to a provider service and meeting MAI or NCD/LCD criteria.
    Medically accepted indication (MAI) for Part B
    DefinitionAn indication may be considered medically accepted for Part B if a clinical reviewer determines it is medically accepted based on CMS guidance, major compendia, authoritative literature, and accepted standards of medical practice.
    ApplicabilityUsed when no NCD, LCD, LCA, or other coverage policy exists for the drug/indication.
    Reviewer rolePriority Health Clinical Reviewer or Medical Director assesses unlabeled uses for MAI determination.
    Vaso‑occlusive crisis (VOC)
    DefinitionPain resulting from tissue ischemia caused by vaso‑occlusion, commonly occurring in bone and marrow and presenting suddenly in extremities, chest, or back.
    Clinical relevancePrimary manifestation targeted by therapies to reduce frequency of vaso‑occlusive crises in sickle cell disease.
    SynonymAlso referred to as recurrent acute pain crises (VOC).

    Initial and Product-Specific Coverage Criteria

    Actemra (tocilizumab) Initial Therapy

    Actemra (tocilizumab) — covered when ALL of the following are met

    Actemra initial coverage: Indication is a medically accepted indication not otherwise excluded; medical records supporting the request including documentation of prior therapies and responses are provided; prescriber is a specialist or has consulted with a specialist for the condition being treated; dose and route consistent with FDA labeling or accepted standards of medical practice; coverage duration limited to 2 years.

    Must first try Tyenne prior to Actemra; must not be used concurrently with other biologic drugs, Otezla, or JAK inhibitors; SSc-ILD is not approved for IV administration.

    Adakveo Initial Therapy

    Adakveo — covered when ALL of the following are met

    Adakveo initial coverage: Indication is for reducing vaso-occlusive crises in sickle cell disease per medically accepted indications; medical records supporting the request are provided; patient is age ≥16 years (per indication) or meets labeled age criteria; patient has tried hydroxyurea for 6 months unless there is documented intolerance or contraindication; dose consistent with FDA labeling or accepted standards of practice; coverage duration limited to 2 years.

    Initial Therapy Rules & Common Requirements

    Initial therapy requirements — general initial coverage rules for listed Part B drugs

    Initial therapy requirements — general initial coverage rules for listed Part B drugs

    Initial therapy general: For listed Part B drugs, the indication must be medically accepted and not otherwise excluded; medical records and prior therapy documentation must be provided; prescriber restrictions (specialist/consult) applied where specified; dosing consistent with FDA labeling or accepted standards; step‑therapy requirements (specified per product) must be met prior to approval.

    Coverage durations and product‑specific rules apply; prior authorization form (Medicare Part B Non‑Oncology or Oncology) should be completed as instructed.

    Initial therapy (general)

    Initial therapy — general

    Adakveo initial therapy: Patient must have documentation of a 6‑month trial of hydroxyurea or documented intolerance/contraindication prior to Adakveo authorization; medical records provided; dosing per FDA labeling.6 months

    Reauthorization and Continuation Requirements

    Prior Authorization, Submission, and Documentation Requirements

    Prior Authorization

    Prior authorization required — submit PA form and medical records

    Certain Part B drugs require prior authorization; providers must submit the appropriate Medicare Part B drug request form (Non‑Oncology) or the Oncology Drug Request form/Web Form and include supporting medical records demonstrating a medically accepted indication and prior therapies as applicable to the drug.

    • Use the Medicare Part B (Non‑Oncology) drug request form for non‑oncology Part B drugs and the Medicare Part B Oncology Drug Request form for oncology drugs or the online Web Form to streamline review.
    • Include dose, frequency, place of administration, and required medical records supporting diagnosis and prior therapy trials.
    Step Therapy

    Step therapy may apply to Part B drugs (MAPD members)

    Step therapy may apply to Part B drugs for MAPD members not currently receiving the Part B drug; providers must document trials of required preferred or generic comparators before coverage of the requested Part B product.

    HCPCS / CPT / Diagnostic & Threshold Coding

    Chemotherapy (Avastin) CPT/HCPCSHCPCSCovered
    J9035Bevacizumab (Chemotherapy) — referenced for Avastin group
    Referenced HCPCS for generic docetaxelHCPCS
    J9171Docetaxel
    Required prior product HCPCS examples for BoruzuHCPCS
    J9049Bortezomib, injectable, generic example HCPCS code referenced
    J9041Bortezomib, injectable, generic example HCPCS code referenced
    Codes referenced (none provided in this part)mixed
    N/ANo explicit HCPCS/CPT/NDC codes listed in this document section
    Referenced HCPCSHCPCS
    J9171Docetaxel (generic) — code referenced in Docivyx criteria
    ADAMTS13 activity threshold for Adzynma
    ThresholdADAMTS13 activity < 10% is required to confirm diagnosis for Adzynma (cTTP).
    Diagnostic requirementGenetic testing confirming cTTP must accompany ADAMTS13 activity <10% for initial requests.
    PrescriberMust be prescribed by or in consultation with a specialist for the disease state.
    Hydroxyurea trial duration — Adakveo
    Required durationHydroxyurea trial of 6 months is required prior to Adakveo unless intolerance or contraindication is documented.

    Step Therapy Matrix & Required Prior Trials

    Step therapy principleApplies to
    Trial of a preferred or more cost-effective agent is required before coverage of a non-preferred Part B drug (Step Therapy).
    MAPD members not currently receiving the Part B drug; examples include requiring Tyenne before Actemra and hydroxyurea before Adakveo.
    DrugStep therapy requirement
    Adakveo (crizanlizumab-tmca)
    Patient must first try hydroxyurea for 6 months or have documented intolerance/contraindication prior to Adakveo approval.
    DrugStep therapy requirement
    Alyglo (IVIG)
    For requests determined to be a Part B benefit, member must first try two preferred IVIG products (examples: Gammagard Liquid, Gamunex-C, Privigen) before Alyglo is approved.
    DrugStep therapy requirement
    Avastin (bevacizumab) / biosimilars (Alymsys)
    Must first try the bevacizumab biosimilars Mvasi AND Zirabev prior to approval of Avastin (and Alymsys per product-specific requirement).
    Brand product exampleRequired generic comparator trial
    Axtle (pemetrexed)
    Must first try generic pemetrexed prior to Axtle per step therapy requirements.
    Example productComparator requirement
    Pemetrexed (Axtle)
    Trial of generic pemetrexed with documented failure or intolerance required before Axtle is approved.
    DrugStep therapy requirement
    Cimzia (certolizumab pegol)
    Patient must first try and fail TWO of the listed preferred agents (e.g., a preferred adalimumab product, Rinvoq, Skyrizi, Tyenne, Cosentyx, Otezla, Xeljanz/XR, Yesintek/Selarsdi, or Enbrel) unless contraindicated or not tolerated.
    DrugStep therapy requirement
    Cinryze (C1 inhibitor)
    Trial and documented failure of Haegarda (or contraindication to Haegarda) required prior to approval of Cinryze.
    DrugStep therapy requirement
    Emblaveo (aztreonam–avibactam)
    Must attempt other appropriate generic, susceptible antibiotics (as determined by culture and sensitivity or indicated for empiric therapy) before Emblaveo is approved.
    Example requested productRequired prior agent(s)
    Entyvio (vedolizumab)
    Patient must first try Avsola OR Renflexis before Entyvio.
    DrugStep therapy note
    Evkeeza (evinacumab-dgnb) and Exdensur (depemokimab)
    Step therapy applies per CMS guidance; Evkeeza requires trial of Repatha prior to approval except in children aged 5–9 where Repatha trial is not required; Exdensur subject to step therapy sequencing as specified.

    Quantity Limits & Lifetime Use Restrictions

    Casgevy quantity limit
    Quantity limitCasgevy is limited to 1 lifetime dose (one treatment course per patient).
    Authorization durationInitial authorization duration: 6 months for Casgevy.
    Age requirementPatient must be at least 12 years of age for Casgevy eligibility.
    Encelto quantity limit
    Quantity limitEncelto limited to 1 implant per affected eye per lifetime.
    Age requirementPatient must be ≥ 18 years old for Encelto initial coverage.
    Approval duration

    Administration Setting & Site-of-Care Notes

    Billing Rule

    Infusion/administration site — document infusion center, office, or hospital outpatient

    Part B drugs are typically administered by infusion or injection incident to a provider service; document place of administration (infusion center, office, or hospital outpatient) on the request for accurate billing and coverage.

    • Provide place of administration and any site‑of‑care notes required for billing.
    • No explicit site‑of‑care restrictions are stated in these product entries; follow FDA labeling and accepted standards.
    Note

    Infusion center — submission guidance; no explicit site‑of‑care restrictions in excerpts

    Submit Part B drug requests (Non‑Oncology or Oncology forms or Web Forms) as instructed; the excerpts do not impose explicit site‑of‑care restrictions, but providers must document place of administration when submitting the PA to support billing.

    Biosimilar & Interchangeability Guidance

    Billing Rule

    Biosimilar guidance — FDA supports biosimilars; biosimilar‑first trials may apply

    Cosmetic or non‑medically accepted uses are not included; where biosimilars are appropriate, FDA supports their use and some policies require biosimilar‑first or biosimilar trial sequences (e.g., Avastin biosimilars Mvasi and Zirabev must be tried before Avastin).

    • Biosimilar interchangeability or biosimilar‑first sequencing is enforced per product sections.
    • Document trials of biosimilars and reasons for using the reference product if applicable.
    Step Therapy

    Avastin biosimilar step therapy — try Mvasi and Zirabev first

    For Avastin and related products, providers must document trials of Mvasi and Zirabev prior to approval of Avastin; per NCCN, FDA‑approved biosimilars are appropriate substitutes.

    • Use the Oncology Drug Request form and include documentation of Mvasi and Zirabev trials.
    • Coverage up to 1 year; dosing per FDA labeling.

    Glossary & Key Clinical Definitions

    Hypogonadism diagnostic threshold
    Hypogonadism thresholdTwo separate morning total testosterone measurements <300 ng/dL (or below lab reference range) plus clinical signs/symptoms consistent with testosterone deficiency are required to support diagnosis.
    Measurement timingLevels must be drawn in the morning on separate days due to diurnal variation.
    Clinical correlationTherapy initiation requires both biochemical confirmation and compatible clinical features per Endocrine Society guidance.
    cTTP definition and ADAMTS13 diagnostic approach
    DefinitionCongenital TTP (cTTP) is an inherited deficiency of ADAMTS13; diagnosis is confirmed by genetic testing plus ADAMTS13 activity <10%.
    Diagnostic stepsClinical evaluation with characteristic findings, genetic testing for ADAMTS13 variants, and measurement of ADAMTS13 activity guide diagnosis.

    Common Reasons for Denial & Documentation Triggers

    Denial Risk

    Denial risk — requests not meeting prior authorization criteria may be denied

    If prior authorization criteria are not met, the request may be denied; ensure step therapy trials, diagnostic test results, specialist prescriber requirements, and all required medical records are included with the submission.

    • Denial reasons include missing documentation, unmet step therapy, and failure to meet product‑specific clinical criteria.
    • Review the product section for exact documentation and test requirements to avoid denial.
    Denial Risk

    Denial risk — IVIG step therapy not met may trigger denial

    For IVIG requests, failing to document trials of two preferred IVIG products (when determined a Part B benefit) may result in denial of the requested IVIG product.

    • Include dates, doses, and reasons for inadequate response or intolerance for the two preferred IVIG trials.
    • Refer to LCD L34771 for additional documentation requirements.

    Additional Coding & Diagnostic Thresholds

    Emblaveo affected product listingmixed
    No codes listed
    Products Affected — listed drug names in this sectionmixed
    No codes listed
    Blood eosinophil level thresholds
    Use caseApplied to severe eosinophilic asthma eligibility and Part B determinations in policy.
    DocumentationPrior eosinophil counts and prior therapy responses must be provided in medical records for initial requests.
    MG‑ADL baseline reference
    MG‑ADL referenceMG‑ADL baseline score ≥6 is required for initial coverage of myasthenia gravis therapies (policy reference for Epijkstra/Bkemv).
    MeasurementMG‑ADL is used as a baseline and for reauthorization to document clinical improvement from baseline.
    DocumentationMedical records must include MG‑ADL scores at baseline and follow‑up to support authorization and reauthorization.
    Policy Summary
    Payerpriority health
    PolicyMedicare Part B Prior Authorization and Step Therapy Criteria
    Policy CodePolicy N/A
    Change TypeAdministrative review — no material changes
    Effective DateMay 1, 2026
    Last ReviewMay 1, 2026
    Next Review DateN/A
    Key ActionSubmit the Medicare Part B drug request form or Web Form with required medical records to request prior authorization.
    SourceLink
    On This Page
    Policy Overview & ScopeInitial and Product-Specific Coverage CriteriaInitial Therapy Rules & Common RequirementsReauthorization and Continuation RequirementsPrior Authorization, Submission, and Documentation RequirementsHCPCS / CPT / Diagnostic & Threshold CodingStep Therapy Matrix & Required Prior TrialsQuantity Limits & Lifetime Use RestrictionsAdministration Setting & Site-of-Care NotesBiosimilar & Interchangeability GuidanceGlossary & Key Clinical DefinitionsCommon Reasons for Denial & Documentation TriggersAdditional Coding & Diagnostic ThresholdsPolicy Background & References
    6 months

    Failure to document a 6-month trial of hydroxyurea or intolerance/contraindication may result in denial.

    Adakveo (crizanlizumab-tmca)

    Covered when ALL of the following are met

    Adakveo (crizanlizumab-tmca) initial: 1) Indication: treatment to reduce frequency of vaso-occlusive crises in SCD patients per FDA labeling; 2) Patient meets labeled age criteria (≥16 years where applicable); 3) Medical records supporting the request are provided; 4) Patient has tried hydroxyurea for 6 months unless intolerant or contraindicated; 5) Dose consistent with FDA labeling or accepted standards.6 months

    Coverage duration 2 years; prior hydroxyurea trial required unless documented intolerance/contraindication.

    Adzynma (rADAMTS13)

    Adzynma (rADAMTS13) — covered when ALL of the following are met

    Adzynma initial: Genetic testing confirming congenital thrombotic thrombocytopenic purpura (cTTP) is provided; ADAMTS13 activity is < 10%; medical records including current weight for dosing are provided; prescriber is a specialist or consulted a specialist for the disease state; initial prophylactic dosing frequency every 2 weeks (may be adjusted to weekly with supporting documentation).ADAMTS13 activity <10%

    Initial and reauthorization approvals are for 12 months; reauthorization requires demonstration of clinical benefit (eg decreased TTP events, improved platelet counts).

    Alhemo (anti-TFPI)

    Covered when ALL of the following are met

    Alhemo initial: Indication: routine prophylaxis to prevent or reduce bleeding episodes in hemophilia A or B per labeling; medical records supporting the request provided including prior therapies and responses; for hemophilia A, prior trial and failure of Hemlibra documented when required; patient is ≥12 years of age; prescriber is a hematologist or specialist or consulted one; dosing consistent with FDA labeling or accepted standards.age >=12 years

    Initial and reauthorization approvals are for 12 months; reauthorization requires documentation of clinical benefit such as fewer bleeding episodes or reduced use of replacement/bypassing agents.

    Alyglo (IVIG) - Initial Coverage Criteria

    Covered when ALL of the following are met

    Alyglo covered use: Product is prescribed for a medically accepted indication not otherwise excluded; medical records supporting the request including documentation of prior therapies and responses are provided; dose consistent with FDA labeling or accepted standards of practice.

    Coverage duration: 2 years.

    Documentation: Medical records supporting the request including prior therapies and responses must be provided.

    Use Part B vs Part D determination as applicable.

    Step therapy: If determined a Part B benefit, member must first try two preferred IVIG products (examples: Gammagard Liquid, Gamunex-C, Privigen) prior to coverage of non-preferred IVIG products.two preferred IVIG trials

    Refer to LCD L34771 for additional criteria.

    Alymsys (bevacizumab-maly) - Initial Coverage Criteria

    Covered when ALL of the following are met

    Alymsys covered use: Product is prescribed for a medically accepted indication not otherwise excluded; medical records supporting the request provided; dose consistent with FDA labeling or accepted standards.

    Coverage duration up to 1 year.

    Step therapy: Must first try Mvasi AND Zirabev prior to approval of Alymsys (bevacizumab biosimilar).

    Applied consistent with LCD L37205.

    Amvuttra (vutrisiran) - Initial and Reauthorization Criteria

    Amvuttra (vutrisiran) — covered when ALL of the following are met

    Indication-specific requirements: Covered for FDA-approved indications (hATTR-PN and ATTR-CM) not otherwise excluded; must not be used in combination with TTR stabilizers or other TTR-lowering agents.

    Age >=18 years for labeled indications.

    hATTR-PN initial: Patient has a documented TTR mutation AND baseline Polyneuropathy Disability (PND) score ≤ IIIb AND clinical signs/symptoms of polyneuropathy; medical records supporting these findings are provided.

    Provide required diagnostic documentation; reauthorization requires demonstration of positive clinical response compared to baseline.

    ATTR-CM initial: Patient has NYHA class I–III heart failure with clinical manifestations or prior HF hospitalization AND cardiac imaging (ECHO or CMR) demonstrating involvement AND diagnosis confirmed by tissue biopsy, genetic testing, or radionuclide imaging (99mTc-PYP/DPD/HMDP). If radionuclide imaging used, documentation must show Grade 2 or 3 uptake AND patient must have tried and failed tafamidis (Vyndamax/Vyndaqel).Tc-PYP grade 2 or 3 if radionuclide used

    Provide medical records; reauthorization requires documentation of clinical benefit (eg reduced CV hospitalizations).

    Reauthorization: Documentation demonstrating positive clinical response compared to baseline must be provided (examples: improved neuropathy symptoms, motor function, quality of life, reduced CV hospitalizations).

    Reauthorization duration: 1 year.

    Amvuttra coverage criteria

    Covered when ALL of the following are met

    Amvuttra initial/reauthorization: Member has a diagnosis of hATTR polyneuropathy or ATTR-CM per FDA indication; required diagnostic testing and prior therapy trials documented; for reauthorization, documentation demonstrating positive clinical response compared to baseline is provided.

    Reauthorization duration 1 year; do not combine with other TTR stabilizers or TTR-lowering agents.

    Asceniv coverage criteria

    Covered when ALL of the following are met

    Asceniv (IVIG): Product is prescribed for a medically accepted indication not otherwise excluded; medical records supporting the request provided including documentation of prior therapies and responses; dose consistent with FDA labeling or accepted standards.

    For Part B benefit determinations, must first try two preferred IVIG products; coverage duration up to 2 years.

    Avastin coverage criteria

    Covered when ALL of the following are met

    Avastin (bevacizumab): Request uses the Medicare Part B Oncology drug request form; medical records demonstrating indication and prior therapies/responses provided; member has tried Mvasi AND Zirabev prior to Avastin; dose consistent with FDA labeling or accepted standards.

    Coverage duration up to 1 year; biosimilars are appropriate substitutes per NCCN.

    Aveed coverage criteria

    Covered when ALL of the following are met

    Aveed general: Request uses the Medicare Part B (Non-Oncology) drug request form; medical records supporting the request are provided; prior trials of required generic testosterone therapies documented where applicable; dose consistent with FDA labeling or accepted standards.

    Coverage duration 2 years.

    Aveed — Initial Therapy (hypogonadism)

    Covered for hypogonadism when ALL of the following are met

    Aveed hypogonadism: 1) Must have tried and failed generic intramuscular testosterone (cypionate or enanthate) AND 2) Must have tried and failed a generic topical testosterone therapy AND 3) Two pre-treatment morning total testosterone measurements on separate days <300 ng/dL (or below laboratory reference) AND 4) Clinical signs/symptoms consistent with testosterone deficiency other than erectile dysfunction or decreased libido AND 5) Patient was assigned male at birth.two measurements <300 ng/dL

    Failures defined as inability to improve symptoms or testosterone levels; provide medical records and required documentation.

    Aveed — Gender Dysphoria

    Covered for gender dysphoria when ALL of the following are met

    Aveed gender dysphoria: 1) Must have tried and failed generic intramuscular testosterone (cypionate or enanthate) AND 2) Must have tried and failed a generic topical testosterone therapy AND 3) Medical records supporting gender-affirming hormone therapy per guideline are provided.

    Provide clinical documentation consistent with Endocrine Society guidance for masculinizing GAHT.

    Avgemsi — Initial Therapy

    Covered when ALL of the following are met

    Avgemsi initial: Medical records supporting the request provided; member must first try generic gemcitabine injection (Gemzar) prior to Avgemsi authorization; dosing per FDA labeling or accepted standards.

    Coverage duration up to 1 year.

    Avtozma — Initial Therapy

    Covered when ALL of the following are met

    Avtozma initial: Product is prescribed for a medically accepted indication; medical records supporting the request provided; member must have tried Tyenne prior to Avtozma authorization; prescriber is a specialist or has consulted a specialist; dosing consistent with FDA labeling or accepted standards.

    Must not be used in combination with other biologic drugs, Otezla, or JAK inhibitors; coverage duration up to 2 years.

    Axtle — Initial Therapy

    Covered when ALL of the following are met

    Axtle initial: Medical records supporting the request provided; member must first try generic pemetrexed prior to Axtle authorization; dosing consistent with FDA labeling or accepted standards.

    Coverage duration 1 year.

    Axtle (pemetrexed) — Initial Coverage

    Covered when ALL of the following are met

    Axtle (pemetrexed) coverage: Drug is indicated for a medically accepted oncology indication; provider completes the Medicare Part B Oncology drug request form; medical records documenting prior therapies and responses provided; trial of generic pemetrexed documented; dosing per FDA labeling.

    Coverage duration 1 year.

    Azmiro (testosterone) — Initial Coverage

    Covered when ALL of the following are met

    Azmiro hypogonadism/gender dysphoria: Indication is hypogonadism or gender-affirming masculinizing therapy as applicable; medical records supporting the request provided including prior failure of generic testosterone cypionate (try-and-fail), for hypogonadism two pre-treatment morning total testosterone levels on separate days <300 ng/dL (or below laboratory reference) and compatible clinical signs/symptoms, and patient assigned male at birth where required; dosing per FDA labeling or accepted standards; coverage duration 2 years.two measurements <300 ng/dL

    Failure to document required prior therapy trials or laboratory confirmation may result in denial.

    Beizray / Beizray-Albumin — Initial Coverage

    Covered when ALL of the following are met

    Beizray coverage: Indication is a medically accepted oncology use for docetaxel; provider completes the Medicare Part B Oncology drug request form and supplies medical records documenting prior therapies and responses; member has tried generic docetaxel (Taxotere, HCPCS J9171) prior to Beizray or Beizray-Albumin kit; dosing consistent with FDA labeling or accepted standards.

    Coverage duration 1 year; no demonstrated superiority over generic docetaxel apart from formulation differences.

    Benlysta (Initial and Reauthorization)

    Benlysta (IV) — Covered when ALL of the following are met

    Benlysta general: Indication is a medically accepted use not otherwise excluded; medical records supporting the request including prior therapies and responses are provided; dosing consistent with FDA labeling or accepted standards.

    Must not be used in combination with another biologic drug or Lupkynis.

    SLE initial coverage: SELENA-SLEDAI score ≥6 at baseline AND either anti-dsDNA >30 IU/mL OR ANA titer >1:80 AND patient is receiving standard therapy including at least two of the following agents for ≥12 weeks each (eg steroid, immunosuppressant, hydroxychloroquine).SELENA-SLEDAI >=6; anti-dsDNA >30 IU/mL OR ANA >1:80; two agents >=12 weeks

    Initial authorization 1 year; reauthorization requires evidence of clinical improvement.

    Lupus nephritis initial: Confirmed SLE diagnosis AND kidney biopsy confirming class 3, 4, and/or 5 disease AND receiving standard therapy for lupus nephritis (eg mycophenolate or azathioprine plus steroid).kidney biopsy class 3/4/5

    Initial authorization 1 year; reauthorization requires improved or stable eGFR.

    Bivigam (IVIG)

    Bivigam (IVIG) — Covered when ALL of the following are met

    Bivigam general: Product is prescribed for a medically accepted indication not otherwise excluded; medical records supporting the request including documentation of prior therapies and responses are provided; dose consistent with FDA labeling or accepted standards.

    Coverage duration 2 years.

    IVIG step therapy: If determined a Part B benefit, member must first try two preferred IVIG products (eg Gammagard Liquid, Gamunex-C, Privigen) prior to Bivigam unless otherwise specified.two preferred IVIG trials

    Refer to LCD L34771.

    Bkemv (NMOSD)

    Bkemv — Covered when ALL of the following are met

    NMOSD initial: Patient has AQP4 antibody–positive neuromyelitis optica spectrum disorder (NMOSD); patient has tried and failed Epysqli (inadequate response or intolerance); Bkemv will not be used in combination with Uplizna, Enspryng, Ultomiris, or other NMOSD medications; medical records supporting the request are provided; prescriber is a neurologist or consulted a neurologist.AQP4 antibody positive; prior Epysqli failure

    Initial authorization per product guidance; reauthorization requires decreased relapse rate and supporting records.

    Reauthorization: Bkemv not used in combination with other NMOSD therapies and patient demonstrates decreased relapse rate compared to baseline with supporting medical records.decrease in relapse rate

    Reauthorization duration per policy.

    NMOSD — Initial authorization

    Covered when ALL of the following are met

    NMOSD — Initial authorization: 1) Patient is anti-AQP4 antibody positive; 2) Patient has tried and failed Epysqli (inadequate response or intolerance); 3) Bkemv will not be used in combination with Uplizna, Enspryng, or other NMOSD medications; 4) Medical records supporting the request provided; prescriber is or has consulted a neurologist.

    NMOSD — Reauthorization

    Reauthorization requires ALL of the following

    NMOSD — Reauthorization: 1) Bkemv not used in combination with Ultomiris, Uplizna, Enspryng, or other NMOSD medications; 2) Patient has had a decrease in relapse rate compared to baseline; 3) Medical records supporting the request provided.

    PNH — Initial authorization

    PNH — covered when ALL of the following are met

    PNH — Initial authorization: Diagnosis of paroxysmal nocturnal hemoglobinuria confirmed by flow cytometry; presence of hemolysis-associated symptoms (eg thrombosis, organ dysfunction, pain); Bkemv will not be used in combination with other complement therapies (eg Fabhalta, Ultomiris, Empaveli); patient has tried and failed Epysqli (inadequate response or intolerance); medical records supporting the request provided.

    For reauthorization, must show clinical improvement and sustained hematologic benefit.

    PNH — Reauthorization

    PNH — Reauthorization requires ALL of the following

    PNH — Reauthorization: Bkemv not used in combination with other complement therapy; improvement in PNH-related symptoms compared to baseline and sustained increase in hemoglobin or improved hemolysis or reduced transfusions compared to baseline; medical records supporting the request provided.

    aHUS — Initial authorization

    aHUS — covered when ALL of the following are met

    aHUS — Initial authorization: Shiga toxin–related HUS and TTP have been ruled out; patient has tried and failed Epysqli (inadequate response or intolerance); medical records supporting the request have been provided.

    For reauthorization, must show decreased signs of TMA (eg normalized platelets/LDH, improved creatinine).

    aHUS — Reauthorization

    aHUS — Reauthorization requires ALL of the following

    aHUS — Reauthorization: Patient has had decreased signs of thrombotic microangiopathy (eg normalization of platelet counts and LDH; reduction in serum creatinine) and medical records supporting the request are provided.

    Myasthenia gravis — Initial authorization

    Myasthenia gravis — covered when ALL of the following are met

    Myasthenia gravis — Initial authorization: Baseline MG-ADL score ≥6; diagnosis of generalized myasthenia gravis that is AChR-Ab positive; prior trial and failure of Epysqli (inadequate response or intolerance) AND trial of Vyvgart or Vyvgart Hytrulo with intolerance or inadequate response documented; Bkemv will not be used in combination with chronic IVIG, Vyvgart, Ultomiris, Rystiggo, or Zilbrysq; medical records provided; prescriber is or has consulted a neurologist.MG-ADL >=6

    Reauthorization requires documented improvement in MG-ADL total score and no combination with excluded therapies.

    Myasthenia gravis — Reauthorization

    Reauthorization requires ALL of the following

    Myasthenia gravis — Reauthorization: Bkemv not used in combination with similar MG therapies; documentation of improvement in MG-ADL total score from baseline; medical records supporting the request provided.

    Bomyntra — Step therapy and coverage

    Bomyntra — covered when ALL of the following are met

    Bomyntra initial/step therapy: Medical records supporting the request including documentation of prior therapies and responses provided; patient has tried Wyost, Xtrenbo, AND Bilprevda prior to Bomyntra authorization; dosing per FDA labeling or accepted standards.

    Coverage duration up to 2 years.

    Boruzu — Step therapy and coverage examples

    Boruzu — covered when ALL of the following are met

    Boruzu initial/step therapy: Medical records supporting the request provided including prior therapies and responses; must first try one generic bortezomib injectable product (eg HCPCS J9049 or J9041) prior to Boruzu authorization; dosing per FDA labeling or accepted standards.

    Coverage duration up to 1 year.

    Casgevy — Sickle cell initial authorization

    Casgevy — Sickle cell initial authorization — covered when ALL of the following are met

    Casgevy SCD criteria: Medical records supporting the request provided; genotype-confirmed SCD (βS/βS, βS/β0, or βS/β+) by genetic testing; history of ≥2 severe vaso-occlusive events per year in the previous 2 years despite appropriate supportive care; current weight provided; adequate organ function and eligibility for HSCT documented; no contraindication to products/procedures required for gene therapy; prior trial and failure of hydroxyurea or if intolerant at least one other SCD treatment (eg Endari) documented.age >=12 years; >=2 VOEs/year

    Authorization duration 6 months; limit one lifetime dose; not covered in patients with prior HSCT or prior gene therapy; prescriber must be a hematologist or transplant specialist.

    Casgevy — Beta Thalassemia Initial Coverage

    Casgevy — Beta thalassemia initial authorization — covered when ALL of the following are met

    Casgevy beta thalassemia: Medical records supporting the request provided; diagnosis of transfusion-dependent beta thalassemia defined as ≥100 mL/kg/year or ≥10 units/year pRBC in the previous 2 years; no known and available HLA-matched donor per hematologist/transplant specialist; provider attests that patient would be clinically stable and eligible for HSCT in absence of a matched donor; age ≥12 years; prescriber is a hematologist or transplant specialist.transfusion threshold >=100 mL/kg/year or >=10 units/year

    Authorization duration 6 months; limit one lifetime dose; not covered if prior HSCT or prior gene therapy.

    Casgevy — SCD Initial Coverage (detailed SCD criteria)

    Covered when ALL of the following are met for Sickle Cell Disease:

    Casgevy SCD full criteria: 1) Medical records supporting the request provided; 2) Diagnosis of SCD with βS/βS, βS/β0, or βS/β+ genotype confirmed by genetic testing; 3) History of ≥2 severe VOCs per year in the prior 2 years; 4) Current weight provided; 5) Adequate organ function and eligibility for HSCT; 6) No contraindication to any product or procedure required for gene therapy; 7) Prior trial and failure of hydroxyurea or, if not tolerated, at least one other SCD therapy (eg Endari).age >=12 years; authorization 6 months; limit one lifetime dose

    Not covered if prior HSCT or prior gene therapy; prescriber must be a hematologist or transplant specialist.

    Casgevy — Beta Thalassemia Initial Coverage (detailed)

    Covered when ALL of the following are met for transfusion-dependent beta thalassemia:

    Casgevy Beta thalassemia full criteria: 1) Medical records supporting the request provided; 2) Diagnosis of transfusion-dependent beta thalassemia (≥100 mL/kg/year or ≥10 units/year pRBC in prior 2 years); 3) No known and available HLA-matched donor as determined by hematologist/transplant specialist; 4) Provider attests patient would be clinically stable and eligible for HSCT in absence of matched donor.age >=12 years; authorization 6 months; limit one lifetime dose

    Not covered if prior HSCT or prior gene therapy; prescriber must be a hematologist or transplant specialist.

    Cimzia — Initial Coverage and Step Therapy

    Cimzia — Covered when ALL of the following are met

    Cimzia criteria: Indication is an FDA‑approved or medically accepted use; prescriber is a specialist or has consulted a specialist; not used in combination with other biologics, Otezla, or JAK inhibitors; patient has tried and failed two listed preferred agents (unless contraindicated or intolerant) as specified in policy; medical records supporting the request provided.two prior agent failures unless contraindicated

    Coverage duration 2 years; dosing per FDA labeling.

    Cinqair — Initial Coverage

    Cinqair — Covered when ALL of the following are met

    Cinqair criteria: Medical records supporting the request including documentation of prior therapies and responses are provided; patient's current weight is provided; for severe eosinophilic asthma, blood eosinophils ≥150 cells/mcL at therapy start OR ≥300 cells/mcL in the previous 12 months; prescriber is a specialist or has consulted with a specialist; dosing per FDA labeling.eosinophils >=150 cells/mcL at start OR >=300 cells/mcL in prior 12 months

    Must not be used in combination with other biologic drugs; reauthorization requires documented clinical benefit.

    Initial therapy criteria — severe eosinophilic asthma (IL‑5 antagonist)

    Covered when ALL of the following are met for initial coverage of severe eosinophilic asthma with an IL‑5 antagonist:

    Documentation: Medical records supporting the request including prior therapies and responses are provided.

    Patient's current weight must be provided.

    Eosinophil biomarker: Blood eosinophils ≥150 cells/mcL at therapy start OR ≥300 cells/mcL in the prior 12 months.>=150 cells/mcL at start OR >=300 cells/mcL prior 12 months
    Prior controller therapy: Trial and failure of 1 ICS/LABA inhaler plus 1 other asthma controller medication in the past 6 months (failure defined as intolerance or lack of improvement after ≥4 weeks).1 ICS/LABA + 1 controller

    Reauthorization / safety considerations

    Reauthorization / safety considerations

    Clinical benefit: Documentation of clinical benefit such as decreased exacerbations, improved symptoms, or decreased oral steroid use must be provided for reauthorization.
    Avoid combination biologics: Do not use in combination with other biologic agents due to increased infection and immunosuppression risk.

    Cosentyx IV coverage criteria

    Cosentyx IV coverage criteria

    Cosentyx IV exclusions: Must not be used in combination with other biologic drugs, Otezla, or JAK inhibitors; medical records supporting the request provided.
    Prescriber is a specialist or has consulted with a specialist for the condition being treated.
    Step therapy: Must first try Avsola, Renflexis OR Simponi Aria prior to Cosentyx IV authorization.

    Coverage duration 2 years; dosing per FDA labeling.

    Cosentyx (secukinumab) Initial Therapy

    Cosentyx (secukinumab) — covered when ALL of the following are met

    Cosentyx initial: Prescriber is a specialist or has consulted with a specialist; medical records supporting the request provided; must first try Avsola, Renflexis OR Simponi Aria; dosing per FDA labeling or accepted standards; coverage duration 2 years.

    Must not be used in combination with other biologic drugs, Otezla, or JAK inhibitors.

    Coverage duration 2 years.

    Adzynma initial therapy (dosing and diagnostic requirements)

    Adzynma initial therapy (dosing and diagnostic requirements)

    Adzynma initial dosing & diagnostics: Genetic testing confirming cTTP and ADAMTS13 activity <10% are required for initial requests; initial prophylactic dosing frequency every 2 weeks (may adjust to weekly with documentation); medical records including current weight provided.ADAMTS13 activity <10%

    Initial and reauthorization approvals for 12 months.

    Alhemo initial therapy

    Alhemo initial therapy

    Alhemo initial: Used for routine prophylaxis in hemophilia A or B with medical records documenting prior therapies and responses; for hemophilia A require prior trial/failure of Hemlibra when specified; patient age ≥12 years; prescriber is a hematologist or specialist; initial and reauthorization approvals for 12 months.age >=12 years

    Reauthorization requires documentation of clinical benefit.

    Initial therapy requirements for multiple products (operational specifics)

    Initial therapy requirements for multiple products (operational specifics)

    IVIG and biosimilars: For IVIG products, determine Part B vs Part D benefit; if Part B, member must first try two preferred IVIG products; for bevacizumab biosimilars (Alymsys) must try Mvasi and Zirabev prior to reference product; medical records and required forms must be submitted.two preferred IVIG trials

    Follow LCD L34771 and LCD L37205 where applicable.

    Amvuttra initial therapy notes

    Amvuttra initial therapy notes

    Amvuttra initial notes: Clinical trial populations and diagnostic expectations differ by indication; Amvuttra is not recommended in combination with other TTR stabilizers or TTR‑lowering agents; documentation of genetic testing and imaging/biopsy where applicable required.

    Reauthorization requires documentation of positive clinical response compared to baseline.

    Azmiro initial therapy

    Azmiro initial therapy

    Azmiro initial trial: Trial and documented failure of generic testosterone cypionate required prior to Azmiro authorization; provide two morning testosterone measurements and clinical documentation for hypogonadism indications.two measurements <300 ng/dL

    Coverage duration 2 years.

    Beizray initial therapy

    Beizray initial therapy

    Beizray initial trial: Trial of generic docetaxel (Taxotere, J9171) required prior to Beizray or Beizray‑Albumin kit authorization; medical records supporting prior therapies and responses provided; dosing per FDA labeling.

    Coverage duration 1 year.

    Benlysta initial therapy

    Benlysta initial therapy

    Benlysta SLE prerequisites: SELENA‑SLEDAI score ≥6 and either anti‑dsDNA >30 IU/mL OR ANA >1:80 at baseline; patient receiving standard therapy including two agents for ≥12 weeks each; medical records provided; prescriber is a specialist or has consulted one.SELENA‑SLEDAI >=6; anti‑dsDNA >30 IU/mL OR ANA >1:80

    Initial authorization 1 year; reauthorization 2 years with evidence of clinical improvement.

    Benlysta lupus nephritis: Confirmed SLE diagnosis and kidney biopsy confirming class 3, 4, and/or 5 disease AND receiving standard LN therapy (eg mycophenolate or azathioprine plus steroid); medical records provided.kidney biopsy class 3/4/5

    Initial therapy rules (summary)

    Initial therapy rules summarized

    Initial therapy summary: Follow indication‑specific diagnostic confirmation, document prior therapy failures per step‑therapy rules, abide prescriber/specialist requirements, and submit required Medicare Part B drug request forms with supporting medical records; dosing approved per FDA labeling or accepted standards.

    Coverage durations and reauthorization rules vary by product.

    Axtle initial therapy

    Axtle initial therapy

    Axtle initial trial: Trial of generic pemetrexed required prior to Axtle authorization; medical records supporting prior therapy and response must be provided.

    Coverage duration 1 year.

    • Step therapy requires trial and documented failure (or intolerance/contraindication) of the specified preferred agent(s) per product.
    • Biosimilars and generics are commonly designated as the required first‑line agents under step therapy.
    Prior Authorization

    Prior authorization form requirement — use Medicare Part B drug request or Oncology form

    Providers must use the Medicare Part B (Non‑Oncology) drug request form, the Medicare Part B Oncology (Cancer Therapy) drug request form, or the Web Form as appropriate to submit prior authorization requests for Part B drugs; including these forms can streamline review.

    • Provide dose, frequency, place of administration, and supporting medical records with the submission.
    • Use the Oncology form/web form for oncology agents (e.g., Axtle, Beizray, Avastin).
    Prior Authorization

    Submit Medicare Part B drug request form or Web Form

    Complete the Medicare Part B drug request form (Non‑Oncology) or the Medicare Part B Oncology form/Web Form to streamline review and avoid processing delays for Part B drug prior authorization submissions.

    • Include required supporting medical records (diagnosis confirmation, prior therapy trials and responses, baseline measures where applicable).
    • Omitting the appropriate form or required records may delay or result in denial.
    Prior Authorization

    Adakveo prior authorization and hydroxyurea trial

    Adakveo requests require prior authorization using the Medicare Part B (Non‑Oncology) drug request form or Web Form; include medical records and documentation that the patient tried hydroxyurea for 6 months or has intolerance/contraindication.

    • Coverage duration: 2 years; dosing per FDA labeling or accepted standards.
    • Document hydroxyurea trial duration (6 months) or documented intolerance/contraindication.
    Prior Authorization

    Adzynma prior authorization — 12‑month approvals and diagnostic proof

    Adzynma initial and reauthorization requests require prior authorization; initial and reauthorization approvals are for 12 months and providers must submit genetic testing confirming cTTP and ADAMTS13 activity < 10% plus medical records.

    • Include patient's current weight for dosing on both initial and reauthorization requests.
    • Prescriber must be, or document consultation with, an appropriate specialist.
    Prior Authorization

    Alhemo prior authorization — 12‑month approvals and required records

    Alhemo requires prior authorization for initial and reauthorization approvals of 12 months; include medical records documenting diagnosis, prior therapies and (for hemophilia A) prior Hemlibra trial/failure where required.

    • Patient must be ≥12 years of age for coverage.
    • Prescriber must be, or document consultation with, a hematologist or appropriate specialist.
    Step Therapy

    Avgemsi prior trial of generic gemcitabine required

    Avgemsi requires step therapy — provider must document a prior trial of generic gemcitabine injection (Gemzar) before coverage of Avgemsi will be approved.

    • Include medical records documenting the generic gemcitabine trial and response.
    • Coverage duration: up to 1 year; dosing per FDA labeling.
    Step Therapy

    Avtozma step therapy — trial Tyenne first

    Avtozma requires step therapy — providers must document trial of Tyenne prior to approval; use the Medicare Part B (Non‑Oncology) drug request form or Web Form and provide medical records.

    • Do not use Avtozma in combination with other biologic drugs, Otezla, or JAK inhibitors (combination use is excluded).
    • Coverage duration: up to 2 years; dosing per FDA labeling.
    Step Therapy

    Axtle step therapy and PA — trial generic pemetrexed required and submit Oncology form

    Axtle requires a documented prior trial of generic pemetrexed before coverage; prior authorization must be submitted with the Medicare Part B Oncology drug request form or Web Form and supporting medical records.

    • Coverage duration: 1 year; dosing per FDA labeling.
    • Provide prior therapy records and treatment responses to avoid denial.
    Prior Authorization

    Axtle prior authorization — Oncology form and documentation required

    Axtle prior authorization: submit the Medicare Part B Oncology drug request form or Web Form with supporting medical records documenting prior therapies and responses; coverage is typically for 1 year with dosing per FDA labeling.

    • Failure to provide the required medical records may result in denial.
    • Ensure the generic pemetrexed trial is documented in the submission.
    Prior Authorization

    Azmiro prior authorization — submit Non‑Oncology form and hypogonadism documentation

    Azmiro prior authorization: providers must submit the Medicare Part B (Non‑Oncology) drug request form or Web Form with required medical documentation; include documentation of prior failure of generic testosterone cypionate and two pre‑treatment morning total testosterone measurements when applicable.

    • Coverage duration: 2 years; dosing per FDA labeling or accepted standards.
    • For hypogonadism, include two morning total testosterone values <300 ng/dL on separate days and clinical signs beyond erectile dysfunction/decreased libido.
    Prior Authorization

    Beizray prior authorization — Oncology form and generic docetaxel step

    Beizray prior authorization: oncology requests must be submitted via the Medicare Part B Oncology drug request form or Web Form with supporting medical records; providers must document prior trial of generic docetaxel (Taxotere, J9171).

    • Coverage duration: 1 year; dose approved per FDA labeling or accepted standards.
    • Lack of supporting medical records may lead to denial.
    Prior Authorization

    Beizray‑Albumin prior authorization — Oncology form and documentation required

    Beizray‑Albumin prior authorization: submit the Medicare Part B Oncology drug request form or Web Form with supporting records and document prior trial of generic docetaxel; coverage duration is typically 1 year.

    • Dose will be approved per FDA labeling; absence of medical records may result in denial.
    • Beizray products require documentation of prior therapies and responses.
    Prior Authorization

    Prior authorization required — document indication‑specific criteria and prior therapy failures

    The policy lists many Part B drugs that require prior authorization; providers must document indication‑specific criteria, prior therapy failures, and prescriber requirements when submitting requests.

    • Provide diagnosis confirmation, prior therapy trials and responses, and any specialist consultation or prescriber restriction documentation.
    • Coverage durations and other product‑specific requirements vary by drug (see product entries).
    Note

    Authorization durations — product‑specific time limits and lifetime limits

    Prior authorization approvals have product‑specific durations and limits; examples include Casgevy (authorization 6 months; one lifetime dose), Cimzia (coverage duration 2 years), and others — confirm the product entry for the exact duration.

    • Casgevy: 6‑month authorization; limit one dose per lifetime.
    • Verify coverage duration listed in each product's criteria before submitting a request.
    Prior Authorization

    Prior authorization submission — include supporting medical records and specialist involvement when required

    Prior authorization submissions must include supporting medical records documenting prior therapies and responses; for many products prescribers must be specialists or document specialist consultation.

    • Where specified (e.g., NMOSD, myasthenia gravis), prescriptions must be by or in consultation with a neurologist.
    • Omitting specialist prescriber documentation or prior therapy records may result in denial.
    Prior Authorization

    Prior authorization required for listed Part B drugs — use the appropriate Medicare Part B forms

    A list of Part B drugs in this policy require prior authorization via the Medicare Part B (Non‑Oncology) drug request form or Oncology Web Form; submit the appropriate form and supporting records for the named products to streamline review.

    • Oncology agents: use the Medicare Part B Oncology drug request form/Web Form.
    • Non‑oncology Part B drugs: use the Medicare Part B (Non‑Oncology) drug request form or Web Form.
    Prior Authorization

    Medicare Part B drug request form — submit with product‑specific documentation

    Submit the Medicare Part B (Non‑Oncology) drug request form or Web Form to streamline review for Part B drugs; include product‑level required documentation per the product's criteria.

    • Using the correct form reduces processing time and clarifies required billing information (dose, frequency, place of administration).
    • Product‑specific required records (diagnostics, prior therapy trials, specialist consults) must be attached.
    Prior Authorization

    Elevidys prior authorization and 1‑year approval — genetic and antibody documentation required

    Elevidys initial and reauthorization approvals are for 1 year; prior authorization requires documentation per the Elevidys prescribing information (genetic confirmation, anti‑AAVrh74 titer <1:400, and absence of deletions in exon 8 or exon 9).

    • Prescriber must be, or consult with, a neurologist experienced in DMD.
    • Failure to document required genetic/antibody criteria may render the member ineligible.
    Prior Authorization

    Emblaveo prior authorization — 6‑month coverage and microbiology/susceptibility documentation

    Emblaveo coverage is limited to 6 months; prior authorization requires culture and sensitivity results (or suspected organisms) and documentation that other appropriate generic/susceptible antibiotics were tried or are not appropriate.

    • Prescriber must be an infectious disease specialist or document consultation with one.
    • Include microbiology (culture/sensitivity) results or a statement of suspected organism(s) if cultures unavailable.
    Prior Authorization

    Encelto prior authorization — implant limit and required diagnostics

    Encelto approvals are limited to 6 months and to one implant per affected eye per lifetime; prior authorization requires diagnostic testing supporting MacTel type 2 (e.g., FA, OCT), EZ (IS/OS) break measurement between 0.16 and 2.00 mm², and BCVA ETDRS score ≥54 letters.

    • Prescriber must be, or consult with, an ophthalmologist; include required imaging and visual acuity data in the submission.
    • One implant per affected eye lifetime limit must be documented in the request.
    Prior Authorization

    Enjaymo duration & reauthorization — initial 6 months, reauth requires clinical benefit

    Enjaymo initial approval is 6 months; reauthorization requires documentation of clinical benefit (increase in hemoglobin and decreased transfusions) for a 12‑month reauthorization period.

    • Provide baseline hemoglobin, documentation of at least one transfusion within 6 months prior to initiation, current weight, and details of prior rituximab‑containing regimen trial and failure.
    • Prescriber should be, or consult with, a hematologist.
    Step Therapy

    Prior authorization and step requirements — complete PA form and show required step trials

    Prior authorization requires completion of the Medicare Part B drug request form and step therapy must be met where applicable (for example: Entyvio requires trial of Avsola OR Renflexis; Epogen requires trials of Procrit AND Retacrit).

    • Document the specific prior agents tried and outcomes in the medical records.
    • Failure to document required step therapy may result in denial.
    Prior Authorization

    Medicare Part B prior authorization — use Part B forms and attach required records

    Medicare Part B prior authorization: for listed Part B drugs submit the Medicare Part B (Non‑Oncology) drug request form or Web Form and include required medical records and diagnostic proof as specified in the product criteria.

    • Follow product‑specific instructions for diagnostics, specialist involvement, and prior therapy documentation.
    • Use the Part B vs Part D Drug Request form when benefit determination is needed.
    Denial Risk

    Denial risk — unmet prior authorization criteria may result in denial

    Requests that do not meet prior authorization criteria may be denied; ensure the submission meets all listed clinical and documentation requirements.

    • Common causes for denial include missing medical records, absent diagnostic tests, and failure to document required prior therapy trials.
    • Use the specified PA form and attach all required supporting documentation to reduce denial risk.
    Denial Risk

    Adakveo denial risk — missing 6‑month hydroxyurea trial

    Adakveo denial trigger: failure to document a 6‑month hydroxyurea trial or documented intolerance/contraindication may result in denial of the request.

    • If hydroxyurea was not used, provide documentation of medical rationale (intolerance or contraindication).
    • Include hydroxyurea treatment dates and response in submitted records.
    Rationale
    Expert guidance notes clinical response to hydroxyurea may take 3–6 months; 6 months recommended before declaring treatment failure.
    Coverage noteAdakveo coverage contingent on documentation of trial or intolerance/contraindication; coverage duration typically 2 years.
    Alhemo minimum age
    Minimum agePatient must be at least 12 years of age for Alhemo initial coverage.
    Indication contextUsed for routine prophylaxis to prevent or reduce bleeding episodes in hemophilia A or B.
    PrescriberMust be prescribed by or in consultation with a hematologist or other specialist.
    Tc‑PYP diagnostic uptake — ATTR‑CM
    Diagnostic criterionTc‑PYP radionuclide imaging with Grade 2 or 3 cardiac uptake confirms ATTR‑CM diagnosis with high specificity in absence of monoclonal protein.
    UseWhen radionuclide imaging is used to confirm ATTR‑CM, Grade 2 or 3 uptake is required per policy and guidance.
    Complementary testsGenetic testing recommended post‑diagnosis to distinguish hereditary vs wild‑type ATTR‑CM.
    Morning total testosterone threshold
    Diagnostic thresholdMorning total testosterone <300 ng/dL on two separate morning measurements supports hypogonadism diagnosis.
    Measurement timingLevels should be measured in the morning on two separate days due to diurnal variation.
    Clinical correlationLow measurements must be accompanied by clinical signs or symptoms of testosterone deficiency to support treatment.
    SLE disease activity measures (Benlysta)
    SELENA‑SLEDAISELENA‑SLEDAI score ≥ 6 is required for Benlysta SLE initial coverage.
    Anti‑dsDNAAnti‑dsDNA antibody > 30 IU/mL supports active SLE when paired with SELENA‑SLEDAI ≥6.
    ANA titerANA titer > 1:80 is an alternate serologic requirement alongside SELENA‑SLEDAI ≥6.
    MG‑ADL baseline score requirement
    MG‑ADL baselineBaseline MG‑ADL total score ≥ 6 is required for myasthenia gravis coverage criteria.
    Diagnosis requirementGeneralized MG must be anti‑AChR antibody positive.
    Prior therapiesDocumentation of trials (non‑steroid immunosuppressant ≥6 months and Vyvgart trial) required before Epijkstra/Bkemv in MG context.
    Sickle cell vaso‑occlusive events threshold
    VOC thresholdHistory of ≥ 2 severe vaso‑occlusive events per year in the previous 2 years is required for Casgevy SCD eligibility.
    DocumentationGenotype confirmation (βS/βS, βS/β0, or βS/β+) and medical records supporting VOE history required.
    Other requirementsCurrent weight, organ function, HSCT eligibility, and prior therapy failure (hydroxyurea or alternate) must be documented.
    Transfusion dependence threshold — beta thalassemia
    Transfusion dependenceTransfusion dependence defined as ≥100 mL/kg/year OR ≥10 units/year packed RBCs in the previous 2 years for beta thalassemia eligibility.
    DocumentationMedical records must document transfusion history and absence of an available HLA‑matched donor for Casgevy beta thalassemia criteria.
    Other requirementsProvider attestation regarding HSCT eligibility required; prescriber must be hematologist or transplant specialist.
    anti‑AAVrh74 titer requirement — Elevidys
    Anti‑AAVrh74 titerAnti‑AAVrh74 total binding antibody titer < 1:400 is required for Elevidys eligibility per policy and PI.
    Genetic exclusionElevidys is contraindicated in patients with any deletion in exon 8 and/or exon 9 of the DMD gene and such deletions must be excluded.
    PrescriberPrescriber must be or consult with a neurologist experienced in DMD.
    Encelto diagnostic thresholds (EZ area & BCVA)
    EZ break areaEllipsoid zone (EZ) break area between 0.16 and 2.00 mm^2 is required for Encelto eligibility.
    BCVA thresholdBCVA ETDRS score of 54 letters or better (≈20/80 or better) is required.
    Diagnostic supportFA, OCT and exclusion of neovascular MacTel must be documented; prescriber must be or consult an ophthalmologist.
    Enjaymo transfusion timeframe requirement
    Transfusion timeframeAt least one blood transfusion within 6 months prior to initiation is required for Enjaymo (cold agglutinin disease) initial coverage.
    Other requirementsConfirmed CAD diagnosis, symptomatic disease, baseline hemoglobin and weight, and documented trial/failure of a rituximab‑containing regimen are required.
    ReauthorizationReauthorization requires documented clinical benefit (increased Hgb and decreased transfusions).
    Evenity fracture‑risk and bisphosphonate failure criteria
    T‑score pathwayEvenity eligibility pathway: T‑score ≤ −3.0 OR T‑score ≤ −2.5 with a fragility fracture (very high fracture risk).
    Bisphosphonate failure pathwayAlternatively, documented failure/intolerance of oral bisphosphonate plus zoledronic acid or Jubbonti qualifies (failure defined as intolerance, decreased BMD vs prior DEXA, new fracture on therapy, or contraindication).
    Lifetime limitEvenity cumulative use >12 months (lifetime) is excluded per policy.
    Initial approval duration: 6 months.
    Elevidys approval duration control
    Authorization controlElevidys approvals (initial and reauthorization) are issued for 1 year and used as the authorization/quantity control for this one‑time gene therapy.
    Eligibility checksCoverage contingent on genetic confirmation, excluded exon deletions, and anti‑AAVrh74 titer <1:400 prior to authorization.
    Prescriber rolePrescriber must be or consult with a neurologist experienced in DMD for Elevidys requests.
    Denial Risk

    Evenity lifetime limit — requests >12 months per lifetime excluded

    Evenity requests exceeding a cumulative use of more than 12 months per lifetime will be denied; include prior Evenity dosing history to confirm lifetime use does not exceed 12 months.

    • Coverage duration is 12 months per lifetime; attest to prior Evenity exposure on requests.
    • If prior bisphosphonate pathway requirements apply, document those trials or very high fracture‑risk criteria.
    • Use the Oncology form for cancer therapies; include infusion site and relevant billing details.
    • Provide medical records and dosing details to align with coverage and billing requirements.
    Billing Rule

    Dose approvals — follow FDA labeling or accepted standards

    When dosing approvals are requested, dose will be approved according to FDA labeling or accepted standards of medical practice; include dosing rationale and any weight‑based calculations in the submission.

    • For oncology and specialty drugs, indicate the FDA‑approved regimen or accepted standard used for dosing decisions.
    • Document current patient weight when dosing is weight‑based.
    Billing Rule

    Infusion/administration — document site of care (infusion center/office/hospital outpatient)

    Part B drugs are typically administered incident to a provider in an infusion center, office, or hospital outpatient setting; providers must document place of administration on the PA to support appropriate billing.

    • Indicate infusion center, office, or hospital outpatient on the request form.
    • No explicit site‑of‑care restrictions are specified in these excerpts; follow FDA labeling and accepted standards.
    Billing Rule

    Avtozma biosimilar — FDA supports use

    Avtozma is a biosimilar to Actemra and FDA supports use of approved biosimilars; follow product‑specific step therapy and documentation requirements.

    • Document prior therapy trials and prescriber specialty when requesting Avtozma.
    • Do not use in combination with other biologics, Otezla, or JAK inhibitors.
    Billing Rule

    Interchangeable biosimilars — follow product criteria and boxed warnings

    FDA has determined that certain biosimilars (e.g., Bkemv/Epysqil) are interchangeable with their reference products; providers should follow the product‑specific criteria and boxed warnings (e.g., meningococcal infection risk with complement inhibitors).

    • Ensure meningococcal vaccine/risk mitigation per labeling when applicable for complement inhibitors.
    • Provide documentation of prior therapies and indication‑specific tests.
    Note
    Billing Rule

    Actemra and biosimilars — FDA supports biosimilar use

    FDA supports biosimilars as highly similar to reference biologics (e.g., Actemra biosimilars); where biosimilars are appropriate substitutes, providers should follow product‑specific step therapy and substitution guidance.

    • Document prior biosimilar trials or reasons for selecting the reference product.
    • Biosimilar interchangeability designations (when present) permit substitution consistent with FDA guidance.
    Note
    Therapeutic implicationReplacement rADAMTS13 (Adzynma) requires documented genetic confirmation and ADAMTS13 activity <10% for coverage.
    hATTR‑PN and ATTR‑CM definitions
    hATTR‑PNHereditary transthyretin‑mediated amyloidosis with polyneuropathy (hATTR‑PN): requires TTR mutation and clinical neuropathy signs for Amvuttra coverage.
    ATTR‑CMTransthyretin‑mediated amyloid cardiomyopathy (ATTR‑CM): diagnosis requires imaging (ECHO/CMR) and confirmation by biopsy, genetics, or radionuclide imaging (Tc‑PYP Grade 2/3).
    Treatment noteAmvuttra not approved for primary light‑chain amyloidosis and prior tafamidis failure is required for ATTR‑CM pathway.
    Tc‑PYP scan grade 2 or 3 definition
    DefinitionTc‑PYP scan Grade 2 or 3 uptake indicates ATTR‑CM on radionuclide imaging and confers high specificity when monoclonal protein is absent.
    Diagnostic roleGrade 2/3 uptake can confirm ATTR‑CM without biopsy in appropriate clinical context.
    Type 2 inflammation definition
    Type 2 inflammationDefined as blood eosinophils ≥150 cells/µL and/or FeNO ≥20 ppb and/or sputum eosinophils ≥2% and/or clinically allergen‑driven asthma.
    Clinical relevanceUsed to identify patients who may benefit from type‑2 targeted biologics for severe eosinophilic asthma.
    Biomarker thresholdsEosinophil thresholds commonly applied: ≥150 cells/mcL at initiation or ≥300 cells/mcL in prior 12 months per product criteria.
    NMOSD definition and AQP4 antibody requirement
    NMOSD definitionNeuromyelitis optica spectrum disorder is a demyelinating CNS disease often associated with anti‑AQP4 antibody positivity; policy requires AQP4 antibody positive test for coverage of NMOSD biologics.
    AQP4 requirementAQP4 antibody positivity is required for NMOSD initial coverage of Bkemv/Epijkstra per policy.
    PrescriberPrescriptions for NMOSD should be by or in consultation with a neurologist.
    HoFH definition
    DefinitionHomozygous familial hypercholesterolemia (HoFH) is a genetic condition characterized by markedly elevated LDL‑C often due to LDLR mutations; Evkeeza is indicated as adjunct therapy for HoFH.
    Therapeutic contextEvkeeza (ANGPTL3 inhibitor) is used adjunctively to other LDL‑C lowering therapies in HoFH per policy.
    Initial coverage duration (typical)
    Typical durationInitial coverage durations for many Part B drugs are typically 2 years unless otherwise specified.
    ExceptionsSome products (e.g., Elevidys, Amvuttra, Encelto, Enjaymo) have shorter initial or reauthorization durations as specified in product sections.
    Denial Risk

    Denial risk — missing Amvuttra diagnostic or prior therapy requirements

    For Amvuttra, missing required diagnostic confirmation (TTR mutation for hATTR‑PN or specified imaging/biopsy for ATTR‑CM) or lack of documented prior tafamidis failure for ATTR‑CM may result in denial.

    • Provide TTR genetic testing for hATTR‑PN and radionuclide imaging grade when used for ATTR‑CM.
    • Document prior tafamidis trial and outcome for ATTR‑CM requests.
    Denial Risk

    Amvuttra reauthorization risk — document positive clinical response

    At reauthorization for Amvuttra, lack of documentation demonstrating positive clinical response compared to baseline (e.g., improved neuropathy, motor function, QoL, or reduced CV hospitalizations) may lead to denial.

    • Submit measurable clinical outcomes compared to baseline to support continued coverage.
    • Reauthorization duration: 1 year.
    Denial Risk

    Denial risk — Aveed hypogonadism documentation missing may cause denial

    For Aveed, requests lacking documentation of prior failures of generic intramuscular testosterone (cypionate or enanthate), a generic topical testosterone, and two pre‑treatment morning total testosterone measurements <300 ng/dL (plus required clinical signs and birth assignment where applicable) may be denied.

    • Provide two separate morning total testosterone measurements and documentation of prior generic testosterone trials and outcomes.
    • Include clinical signs consistent with testosterone deficiency (beyond ED or decreased libido) when applicable.
    Denial Risk

    Denial risk — missing step therapy trials may lead to denial

    If required step therapy trials are not completed (e.g., required prior therapies for Entyvio, Epogen, or Epysqli), the request may be denied; include documentation of trials and failures or documented contraindications.

    • Entyvio requires prior trial of Avsola OR Renflexis.
    • Epogen requires trials of Procrit AND Retacrit for non‑ESRD Part B requests.
    Denial Risk

    Denial risk — Elevidys eligibility requirements must be met or request may be denied

    For Elevidys, failure to meet genetic, age/ambulatory, or anti‑AAVrh74 antibody titer criteria may trigger denial; document the required genetic testing, ambulatory status, and anti‑AAVrh74 titer <1:400.

    • Elevidys is contraindicated in patients with deletions in exon 8 or exon 9 of the DMD gene.
    • Provide anti‑AAVrh74 total binding antibody titer results (<1:400) on the PA submission.
    Note